Abstract:

Aim: The aim of this studay is to examine the relationship betwen CD163 expression and prognosis in pediatrik Hodgkin lymphoma cases. Material-methods: In this study retrospectively; twenty-one pediatric patients were included who were treated and followed-up with the diagnosis of Hodgkin Lymphoma (HL) in the Pediatric Oncology and Hematology Clinics of Prof. Dr. Cemil Taşcıoğlu City Hospital, between January 2014 and December 2020. CD163 immunohistochemistry was applied to the initial diagnostic biopsies of the cases. Results: The ages of the cases ranged from 6 to 17, with 4.8% (n=1) Stage 1, 28.6% (n=6) Stage 2, 33.3% (n=7) Stage 3, 33.3% (n=7) were diagnosed as Stage 4. B symptoms were present in 42.9% (n=9) of the cases, progression in 15% (n=3), and spleen involvement in 38% (n=8). Histological subtype distributions; 4.8% (n=1) lymphocyte-poor type, 33.3% (n=7) mixed cellular type, 4.8% (n=1) nodular lymphocyte predominant HL, 57.1% (n=12) nodular sclerosing type. When CD 163 expression values were examined, 38.1% (n=8) of the cases were below 5%, 33.3% (n=7) were between 5-25%, 28.6% (n=7) were 6) It is seen that it is >25%. According to CD163 expression groups, there was no statistically significant difference in terms of gender, age, stage, presence of B symptoms, progression status, histological subtypes and spleen involvement (p>0.05). Conclusion: More extensive studies are required to understand the prognostic significance of CD163 expression in pediatric HL cases.

Keywords: